|Bid||0.00 x 1000|
|Ask||0.00 x 1300|
|Day's Range||104.84 - 109.00|
|52 Week Range||61.61 - 114.20|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||61.20|
|Earnings Date||Jan 20, 2021 - Jan 25, 2021|
|Forward Dividend & Yield||1.44 (1.33%)|
|Ex-Dividend Date||Oct 14, 2020|
|1y Target Est||116.47|
Yahoo Finance's Emily McCormick joins The First Trade with Alexis Christoforous and Brian Sozzi to discuss recent earnings reports from Verizon, Abbott and Biogen.
Abbott Laboratories on Wednesday posted third-quarter earnings and revenue that exceeded Wall Street expectations, as did its earnings guidance for the year, but shares reversed lower.
It's been a banner year so far for Abbott Laboratories (NYSE: ABT). There were plenty of things to like with Abbott's Q3 update. In the same period of 2019, Abbott recorded GAAP earnings of $960 million, or $0.53 per share.